Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

被引：0

作者：

Ondhia, U. ^{[1
]}

Conter, H. ^{[2
]}

Owen, S. ^{[3
]}

Zhou, A. ^{[4
]}

Nam, J. ^{[1
]}

Singh, S. ^{[4
]}

Abdulla, A. ^{[5
]}

Chu, P. ^{[5
]}

Felizzi, F. ^{[5
]}

Sangha, R. ^{[6
]}

机构：

[1] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[2] William Osler Hlth Syst, Brampton, ON, Canada

[3] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[4] Cornerstone Res Grp Inc, Burlington, ON, Canada

[5] F Hoffmann La Roche Ltd, Basel, Switzerland

[6] Cross Canc Inst, Edmonton, AB, Canada

来源：

关键词：

NSCLC; Immunotherapy; Cost-effectiveness;

D O I：

10.1016/j.jtho.2018.08.1724

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.04-17

引用

页码：S928 / S928

页数：1